7Y0C
Crystal structure of BD55-1403 and SARS-CoV-2 Omicron RBD
7Y0C の概要
エントリーDOI | 10.2210/pdb7y0c/pdb |
分子名称 | BD55-1403 Fab light chain, BD55-1403 Fab heavy chain, Spike protein S1, ... (5 entities in total) |
機能のキーワード | sars-cov-2, omicron variants, antibody, viral protein, viral protein-immune system complex, viral protein/immune system |
由来する生物種 | Homo sapiens 詳細 |
タンパク質・核酸の鎖数 | 6 |
化学式量合計 | 139552.38 |
構造登録者 | |
主引用文献 | Cao, Y.,Jian, F.,Zhang, Z.,Yisimayi, A.,Hao, X.,Bao, L.,Yuan, F.,Yu, Y.,Du, S.,Wang, J.,Xiao, T.,Song, W.,Zhang, Y.,Liu, P.,An, R.,Wang, P.,Wang, Y.,Yang, S.,Niu, X.,Zhang, Y.,Gu, Q.,Shao, F.,Hu, Y.,Yin, W.,Zheng, A.,Wang, Y.,Qin, C.,Jin, R.,Xiao, J.,Xie, X.S. Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents. Cell Rep, 41:111845-111845, 2022 Cited by PubMed Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages have escaped most receptor-binding domain (RBD)-targeting therapeutic neutralizing antibodies (NAbs), which proves that previous NAb drug screening strategies are deficient against the fast-evolving SARS-CoV-2. Better broad NAb drug candidate selection methods are needed. Here, we describe a rational approach for identifying RBD-targeting broad SARS-CoV-2 NAb cocktails. Based on high-throughput epitope determination, we propose that broad NAb drugs should target non-immunodominant RBD epitopes to avoid herd-immunity-directed escape mutations. Also, their interacting antigen residues should focus on sarbecovirus conserved sites and associate with critical viral functions, making the antibody-escaping mutations less likely to appear. Following these criteria, a featured non-competing antibody cocktail, SA55+SA58, is identified from a large collection of broad sarbecovirus NAbs isolated from SARS-CoV-2-vaccinated SARS convalescents. SA55+SA58 potently neutralizes ACE2-utilizing sarbecoviruses, including circulating Omicron variants, and could serve as broad SARS-CoV-2 prophylactics to offer long-term protection, especially for individuals who are immunocompromised or with high-risk comorbidities. PubMed: 36493787DOI: 10.1016/j.celrep.2022.111845 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (2.94 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード
